## **Core Concept**
The initial treatment for Chronic Myeloid Leukemia (CML) involves targeting the underlying molecular abnormality causing the disease. CML is characterized by the presence of the **Philadelphia chromosome**, resulting from a reciprocal translocation between chromosomes 9 and 22, creating the **BCR-ABL1 fusion gene**. This gene produces a constitutively active tyrosine kinase that drives the proliferation of leukemic cells.

## **Why the Correct Answer is Right**
The correct answer, **Imatinib**, is a **tyrosine kinase inhibitor (TKI)** specifically designed to target the BCR-ABL1 tyrosine kinase. By inhibiting this kinase, imatinib effectively blocks the proliferation signal in CML cells, inducing apoptosis and reducing the leukemic cell burden. Imatinib was the first drug to specifically target the molecular pathogenesis of CML, revolutionizing its treatment.

## **Why Each Wrong Option is Incorrect**
- **Option A:** This option is incorrect because, although interferon-alpha was used in the treatment of CML before the advent of TKIs, it is not the preferred initial treatment due to its lower efficacy and higher toxicity profile compared to TKIs.
- **Option B:** This option is incorrect as it seems to refer to another medication or class not specifically identified but is not the recommended first-line treatment for CML.
- **Option D:** This option is incorrect because, while **allogeneic hematopoietic stem cell transplantation (HSCT)** is a potentially curative option for CML, especially in advanced phases or in cases of TKI resistance or intolerance, it is not the initial treatment of choice for newly diagnosed CML patients due to its associated risks.

## **Clinical Pearl / High-Yield Fact**
A key point to remember is that the introduction of **TKIs like imatinib** has significantly improved the prognosis of CML patients, making it a chronic disease for many. Monitoring for **BCR-ABL1 mutation status** is crucial in the management of CML, especially in cases of treatment failure or resistance, as certain mutations can confer resistance to specific TKIs.

## **Correct Answer:** . **Imatinib**